|
|
|
LOW HEPATIC EXTRACTION DRUGS
Eg. Warfarin, Phenytoin.
|
Cl |
= | Q |
|||
| .. | |||||
| = | Q |
fu.
Cl |
|||
| __________ |
Where
Cl |
||||
| Q |
|||||
| .. | |||||
| |
Q |
fu.
Cl |
(fu.Cl |
||
| __________ |
|||||
| Q |
|||||
| .. | |||||
| |
fu x |
Cl |
fu
(displacement), Cl![]()
![]()
Ie. restrictive clearance.

When
displacement occurs (fu
) : -
Cl
and Vd
total levels
and free levels quickly return to initial values.
NB Patient now has:
- Lower total levels of drug.
- Increased fu and increased total clearance.
- No change in unbound clearance.
- t½ may
,
or
as
t½
0.693 x Vd = __________
Cl - No change in free (active levels).
Clinical implications:
- No change in therapeutic response.
- Beware when monitoring total plasma levels (dose should not be increased).
HIGH HEPATIC EXTRACTION RATIO DRUGS
Eg. Propranolol, Lignocaine.
|
Cl |
= | Q |
fu.
Cl |
||
| __________ |
|||||
| Q |
|||||
| .. | |||||
| |
Q |
fu.
Cl |
(fu.Cl |
||
| __________ |
|||||
| fu.
Cl |
|||||
| .. | |||||
| |
Q |
no change in Cl
as fu
Hence, changes in the protein binding of high hepatic clearance drugs could theoretically cause changes in free drug levels and therapeutic effect, but no clinically important example of this has yet been demonstrated.
![]() ![]() ![]() |